AzurRx BioPharma has higher earnings, but lower revenue than Aratana Therapeutics.
Insider and Institutional Ownership
13.9% of AzurRx BioPharma shares are held by institutional investors. Comparatively, 68.1% of Aratana Therapeutics shares are held by institutional investors. 7.2% of AzurRx BioPharma shares are held by company insiders. Comparatively, 5.3% of Aratana Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
AzurRx BioPharma beats Aratana Therapeutics on 7 of the 11 factors compared between the two stocks.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. It is also developing NOCITA, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-016, allogeneic adipose-derived stem cells for dogs; and AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications. In addition, the company develops AT-008, a therapeutic candidate for treating canine lymphoma in dogs; and other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; Pacira Pharmaceuticals, Inc. to develop and commercialization of licensed animal health products for NOCITA; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas. Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter .
